115 related articles for article (PubMed ID: 27060774)
21. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with Live Attenuated L. Major and TLR4 Agonist Promotes a Th1 Immune Response and Induces Protection against L. Major Infection in BALB/c Mice.
Noorpisheh Ghadimi S; Farjadian S; Hatam GR; Kalani M; Sarkari B
Iran J Immunol; 2018 Jun; 15(2):74-83. PubMed ID: 29947337
[TBL] [Abstract][Full Text] [Related]
23. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.
Katebi A; Gholami E; Taheri T; Zahedifard F; Habibzadeh S; Taslimi Y; Shokri F; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
Mol Immunol; 2015 Oct; 67(2 Pt B):501-11. PubMed ID: 26298575
[TBL] [Abstract][Full Text] [Related]
24. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
[TBL] [Abstract][Full Text] [Related]
25. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
[TBL] [Abstract][Full Text] [Related]
26. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A
J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
[TBL] [Abstract][Full Text] [Related]
28. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
[TBL] [Abstract][Full Text] [Related]
29. Susceptibility to Leishmania major in IL-4 transgenic mice is not correlated with the lack of a Th1 immune response.
Erb KJ; Blank C; Moll H
Immunol Cell Biol; 1996 Jun; 74(3):239-44. PubMed ID: 8799723
[TBL] [Abstract][Full Text] [Related]
30. A lentiviral vaccine expressing KMP11-HASPB fusion protein increases immune response to Leishmania major in BALB/C.
Mortazavidehkordi N; Fallah A; Abdollahi A; Kia V; Khanahmad H; Najafabadi ZG; Hashemi N; Estiri B; Roudbari Z; Najafi A; Farjadfar A; Hejazi SH
Parasitol Res; 2018 Jul; 117(7):2265-2273. PubMed ID: 29845415
[TBL] [Abstract][Full Text] [Related]
31. Protection induced by Leishmania Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis.
Mehravaran A; Nasab MR; Mirahmadi H; Sharifi I; Alijani E; Nikpoor AR; Akhtari J
Infect Genet Evol; 2019 Jun; 70():27-35. PubMed ID: 30738195
[TBL] [Abstract][Full Text] [Related]
32. PEGylation of cationic liposomes encapsulating soluble Leishmania antigens reduces the adjuvant efficacy of liposomes in murine model.
Naseri H; Eskandari F; Jaafari MR; Khamesipour A; Abbasi A; Badiee A
Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28921566
[TBL] [Abstract][Full Text] [Related]
33. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis.
von Stebut E; Belkaid Y; Nguyen BV; Cushing M; Sacks DL; Udey MC
Eur J Immunol; 2000 Dec; 30(12):3498-506. PubMed ID: 11093169
[TBL] [Abstract][Full Text] [Related]
34. Leishmania braziliensis isolates differing at the genome level display distinctive features in BALB/c mice.
Indiani de Oliveira C; Teixeira MJ; Teixeira CR; Ramos de Jesus J; Bomura Rosato A; Santa da Silva J; Brodskyn C; Barral-Netto M; Barral A
Microbes Infect; 2004 Sep; 6(11):977-84. PubMed ID: 15345228
[TBL] [Abstract][Full Text] [Related]
35. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
[TBL] [Abstract][Full Text] [Related]
36. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
Webb JR; Kaufmann D; Campos-Neto A; Reed SG
J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
[TBL] [Abstract][Full Text] [Related]
37. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
Kahl LP; Scott CA; Lelchuk R; Gregoriadis G; Liew FY
J Immunol; 1989 Jun; 142(12):4441-9. PubMed ID: 2786033
[TBL] [Abstract][Full Text] [Related]
38. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice.
Iborra S; Parody N; Abánades DR; Bonay P; Prates D; Novais FO; Barral-Netto M; Alonso C; Soto M
Microbes Infect; 2008; 10(10-11):1133-41. PubMed ID: 18603012
[TBL] [Abstract][Full Text] [Related]
39. Modulation of the immune response of Balb/c mice against Leishmania major by imuvert.
Taha SM; Tabbara KS
Int J Immunopharmacol; 1997 Aug; 19(8):443-9. PubMed ID: 9568550
[TBL] [Abstract][Full Text] [Related]
40. Effect of Leishmania gerbilli injection on mice immunization against cutaneous leishmaniasis (CL) caused by Leishmania major.
Said A; Ali K; Shahrokh I; Hosein H; Mahin M
Pak J Biol Sci; 2007 Jan; 10(1):196-8. PubMed ID: 19070016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
